These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38307382)

  • 21. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.
    Hosseini K; Soleimani H; Maleki S; Nasrollahizadeh A; Tayebi S; Nelson J; Heffron SP
    BMC Cardiovasc Disord; 2024 Jul; 24(1):395. PubMed ID: 39080549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
    Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
    Bruckert E; Desamericq G; Khachatryan A; Ngo P; Gusto G; Sorio-Vilela F
    Rev Cardiovasc Med; 2020 Dec; 21(4):643-650. PubMed ID: 33388010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
    Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
    Toplak H; Bilitou A; Alber H; Auer J; Clodi M; Ebenbichler C; Fließer-Görzer E; Gelsinger C; Hanusch U; Ludvik B; Maca T; Schober A; Sock R; Speidl WS; Stulnig TM; Weitgasser R; Zirlik A; Koch M; Wienerroither S; Wolowacz SE; Diamand F; Catapano AL
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):364-374. PubMed ID: 37286910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An updated review of lipid-modifying therapy.
    Simons LA
    Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome.
    García RV; García JEP; Navas WD; Salmerón DM; Mateos DB
    J Clin Lipidol; 2022; 16(5):635-642. PubMed ID: 35963739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort.
    Blaum C; Brunner FJ; Goßling A; Kröger F; Bay B; Lorenz T; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Seiffert M; Waldeyer C
    Clin Ther; 2021 Sep; 43(9):1583-1600. PubMed ID: 34462126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage].
    Larina VN; Mironova TN; Larin VG; Makhova UV; Orlov DA; Varlamova YY; Kladovikova OV
    Kardiologiia; 2023 May; 63(4):11-15. PubMed ID: 37165989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.